Summit Therapeutics Inc. Accounts Payable
Summit Therapeutics Inc. (SMMT) had Accounts Payable of $22.90 million as of 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-07-23
- 2026-06-30: Accounts Payable, Current $22.90M.
- 2026-03-31: Accounts Payable, Current $27.55M.
- 2025-12-31: Accounts Payable, Current $20.29M.
- 2025-09-30: Accounts Payable, Current $22.25M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $22.90M 10-Q · filed 2026-07-23 |
| 2026-03-31 | $27.55M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $20.29M 10-Q · filed 2026-07-23 |
| 2025-09-30 | $22.25M 10-Q · filed 2025-10-20 |
| 2025-06-30 | $22.98M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $4.99M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $4.64M 10-K · filed 2026-02-23 |
| 2024-09-30 | $3.25M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $3.34M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $6.37M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $2.67M 10-K · filed 2025-02-24 |
| 2023-09-30 | $3.31M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $987.00K 10-Q · filed 2023-08-09 |
| 2023-03-31 | $710.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $355.00K 10-K · filed 2024-02-20 |
| 2022-09-30 | $1.43M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $3.57M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $6.96M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $4.37M 10-K · filed 2023-03-09 |
| 2021-09-30 | $5.88M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $6.95M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $4.11M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $6.14M 10-K/A · filed 2022-12-21 |
| 2020-09-30 | $2.49M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $3.09M 8-K · filed 2020-09-29 |
| 2019-12-31 | $4.47M 10-K · filed 2021-03-31 |
| 2019-01-31 | $5.80M 8-K · filed 2020-09-29 |
| 2018-01-31 | $6.26M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |